APA (7th ed.) Citation

Falchook, G., Fu, S., Lemech, C., Mckean, M., Azad, A., Gan, H., . . . Meniawy, T. (2022). 747P Phase I study of SAR444245 (SAR'245) as monotherapy (mono) and combined with pembrolizumab (pembro) or cetuximab (cetux) in patients (pts) with advanced solid tumors. Annals of Oncology, 33, S885. https://doi.org/10.1016/j.annonc.2022.07.873

Chicago Style (17th ed.) Citation

Falchook, G.S, et al. "747P Phase I Study of SAR444245 (SAR'245) as Monotherapy (mono) and Combined with Pembrolizumab (pembro) or Cetuximab (cetux) in Patients (pts) with Advanced Solid Tumors." Annals of Oncology 33 (2022): S885. https://doi.org/10.1016/j.annonc.2022.07.873.

MLA (9th ed.) Citation

Falchook, G.S, et al. "747P Phase I Study of SAR444245 (SAR'245) as Monotherapy (mono) and Combined with Pembrolizumab (pembro) or Cetuximab (cetux) in Patients (pts) with Advanced Solid Tumors." Annals of Oncology, vol. 33, 2022, p. S885, https://doi.org/10.1016/j.annonc.2022.07.873.